China Resources Sanjiu Medical & Pharmaceutical Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Wen Duo Wu
Chief executive officer
CN¥9.0m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | 3.4yrs |
| Board average tenure | 3.2yrs |
Recent management updates
Recent updates
We Think You Should Be Aware Of Some Concerning Factors In China Resources Sanjiu Medical & Pharmaceutical's (SZSE:000999) Earnings
Mar 19
Does China Resources Sanjiu Medical & Pharmaceutical (SZSE:000999) Have A Healthy Balance Sheet?
Mar 01Is China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (SZSE:000999) Trading At A 39% Discount?
Jan 03Little Excitement Around China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.'s (SZSE:000999) Earnings
Nov 18Analysts Are Updating Their China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (SZSE:000999) Estimates After Its Second-Quarter Results
Aug 26Does China Resources Sanjiu Medical & Pharmaceutical (SZSE:000999) Have A Healthy Balance Sheet?
Aug 09Investors Aren't Buying China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.'s (SZSE:000999) Earnings
Jul 12China Resources Sanjiu Medical & Pharmaceutical (SZSE:000999) Is Increasing Its Dividend To CN¥1.50
Jun 09CEO
Wen Duo Wu (50 yo)
less than a year
Tenure
CN¥9,000,000
Compensation
Mr. Wen Duo Wu is Chairman of KPC Pharmaceuticals,Inc. from January 22, 2025. He is President of China Resources Sanjiu Medical & Pharmaceutical Co. Ltd.from September 06, 2024 and serves as its Director...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President & Director | less than a year | CN¥9.00m | no data | |
| VP, General Counsel | 13.8yrs | CN¥25.59m | 0.013% CN¥ 7.1m | |
| Vice President | 9.8yrs | CN¥26.32m | 0.016% CN¥ 8.4m | |
| Vice President | 3.4yrs | CN¥24.09m | 0.010% CN¥ 5.4m | |
| CFO & Secretary of the Board | less than a year | no data | no data |
3.4yrs
Average Tenure
51yo
Average Age
Experienced Management: 000999's management team is considered experienced (3.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President & Director | less than a year | CN¥9.00m | no data | |
| VP, General Counsel | 20.1yrs | CN¥25.59m | 0.013% CN¥ 7.1m | |
| Chairman | 7.7yrs | CN¥29.03m | 0.019% CN¥ 10.4m | |
| Chairman of the Supervisory Board | 6.5yrs | no data | no data | |
| Independent Director | 1.3yrs | CN¥1.41m | no data | |
| Non-Independent Director | 3.2yrs | no data | no data | |
| Non-Independent Director | 3.2yrs | no data | no data | |
| Supervisor | 7.1yrs | no data | no data | |
| Director | 2.6yrs | no data | no data | |
| Supervisor | 1.8yrs | no data | no data | |
| Supervisor | less than a year | no data | no data |
3.2yrs
Average Tenure
51yo
Average Age
Experienced Board: 000999's board of directors are considered experienced (3.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/16 02:13 |
| End of Day Share Price | 2025/05/16 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. is covered by 39 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Changming He | BOCI Research Ltd. |
| Jessica Li | BofA Global Research |
| Shuchang Liu | Changjiang Securities Co. LTD. |